FDA Approves Eli Lilly’s Weight-Loss Pill Foundayo, Intensifying Rivalry with Novo Nordisk

Eli Lilly’s once-daily weight-loss pill Foundayo wins FDA approval, offering a flexible oral alternative to injectables at $149/month starting April 6.

By: AXL Media

Published: Apr 2, 2026, 4:18 AM EDT

Source: Reuters

Foundayo Launch and Pricing Strategy

Eli Lilly will officially launch Foundayo on April 6, 2026. In a strategic move to ensure rapid adoption, the company has priced the lowest dose at $149 per month for self-pay customers using the LillyDirect program. This pricing structure is designed to remain competitive with Novo Nordisk’s current oral offerings. Following the initial rollout via LillyDirect, the medication will become available through retail pharmacies and various telehealth platforms.

Foundayo vs. Oral Wegovy: Key Differentiators

The approval sets up a significant market battle centered on patient convenience. While both medications are daily pills, Foundayo offers a logistical advantage:

Administration: Foundayo can be taken at any time of day, with or without food.

Rival Constraints: Novo Nordisk’s oral Wegovy requires patients to take the pill on an empty stomach, 30 minutes before consuming food, water, or other medications.